Imu biosciences

Mapping the immune system in unprecedented detail and scale.

Skip to main content. Published: Jan 24, IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare.

Imu biosciences

.

Our focus encompasses the entirety of the imu biosciences journey, including early detection, precise patient stratification, and advanced monitoring for responses, toxicity, and potential relapse.

.

Adversity breeds innovation- It is both strange and unsettling to realise that the biggest leaps in science and technology that benefit society, most frequently occur after severe tragedy. The boost in technological advancements and innovation following both world wars are a prime example. If the past is any indication, the horrors and hardships of the pandemic should soon bear fruit. IMU Biosciences is at the forefront of combining deep, systems-level immune profiling, with its proprietary AI platform to construct an intricately detailed immune atlas that spans human health and disease. Additionally, it offers real-time immune monitoring throughout the patient journey to enhance therapeutic impact and safety. This application significantly improves manufacturing efficiency, a critical challenge in the burgeoning field of cell therapy. Dr Tom Hayday , CSO, and Co-founder of IMU Biosciences emphasised the potential transformative impact of their technology on patient stratification for advanced therapies, disease monitoring, and diagnostics.

Imu biosciences

IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare. Applying AI-driven data analytics to immunology research crystalised further when COVID emerged, and the team leveraged its technology to understand the human immune response to the virus. IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies. The Company was initially seed funded by the European technology investor Kfund and other angel investors. They believe is their role to support the visionary entrepreneurs who will invent the future. Currently, Molten Ventures is a shareholder in a diverse portfolio of companies including Revolut, Trustpilot, Ledger and Thought Machine.

Crush xxx

Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. Applying AI-driven data analytics to immunology research crystalised further when COVID emerged, and the team leveraged its technology to understand the human immune response to the virus. Mapping the immune system in unprecedented detail and scale. IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. About LifeX Ventures LifeX Ventures is a New York-based venture capital firm investing in global visionary entrepreneurs using software and AI to develop transformational solutions that will extend the life of humans and the planet. IMU is founded on the belief that leveraging deep, systems-level immunophenotyping at a population scale, combined with the latest advancements in AI and ML, is essential for unlocking the immense potential of the immune system as a tool in the development of precision immune medicines. She spent three years in the US, gaining international industry and healthcare experience, as Chief of Staff in a commercial stage molecular diagnostics company and as Entrepreneur in Residence at Duke University. This includes the management of refractory diseases and the discovery of novel therapeutic targets. IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies. Tim is Executive Partner at Abingworth, a leading international life sciences investment group, and brings more than 30 years of international investor and management experience in the life sciences industry. Published: Jan 24, All rights reserved. For more information please visit: www. IMU is extending these advanced methodologies to novel research areas, including the study of psychosis, broadening the horizons of medical research and patient care. Our focus encompasses the entirety of the patient journey, including early detection, precise patient stratification, and advanced monitoring for responses, toxicity, and potential relapse.

IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease.

IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies. The Company was initially seed funded by the European technology investor Kfund and other angel investors. IMU is founded on the belief that leveraging deep, systems-level immunophenotyping at a population scale, combined with the latest advancements in AI and ML, is essential for unlocking the immense potential of the immune system as a tool in the development of precision immune medicines. About Kfund Kfund is a family of funds supporting the best tech entrepreneurs in all their stages multistage while covering all their needs multiproduct , across Southern Europe and Latam. Our science the imu platform Learn more. Published: Jan 24, Tim is Executive Partner at Abingworth, a leading international life sciences investment group, and brings more than 30 years of international investor and management experience in the life sciences industry. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. Our focus encompasses the entirety of the patient journey, including early detection, precise patient stratification, and advanced monitoring for responses, toxicity, and potential relapse. Skip to main content. Mapping the immune system in unprecedented detail and scale. For more information please visit: www. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. We are driven by the belief that in the future, no medical decision will be made without truly understanding a patient's immune system, heralding a new era of precision healthcare.